These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Diener HC; Sacco R; Yusuf S; ; Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887 [TBL] [Abstract][Full Text] [Related]
4. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention. Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182 [No Abstract] [Full Text] [Related]
5. Antithrombotic drugs for the secondary prevention of ischemic stroke. Nenci GG; Goracci S Ann Ital Med Int; 2000; 15(4):282-90. PubMed ID: 11202630 [TBL] [Abstract][Full Text] [Related]
6. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Patrono C; Coller B; Dalen JE; Fuster V; Gent M; Harker LA; Hirsh J; Roth G Chest; 1998 Nov; 114(5 Suppl):470S-488S. PubMed ID: 9822058 [No Abstract] [Full Text] [Related]
7. Counting the true cost of antiplatelet therapy for stroke prevention. Morton JA; Newton J; Gray CS Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405 [No Abstract] [Full Text] [Related]
9. Aspirin in patients with coronary artery disease: is it simply irresistible? Nair GV; Davis CJ; McKenzie ME; Lowry DR; Serebruany VL J Thromb Thrombolysis; 2001 Apr; 11(2):117-26. PubMed ID: 11406726 [No Abstract] [Full Text] [Related]
10. [Antithrombotic therapy in ischemic stroke and transient ischemic attack]. Overgaard K; Poulsen TS; Husted SE Ugeskr Laeger; 2007 Oct; 169(40):3379-82. PubMed ID: 17953858 [TBL] [Abstract][Full Text] [Related]
11. The approach to optimizing stroke care. Panagos PD Am J Emerg Med; 2008 Sep; 26(7):808-16. PubMed ID: 18774049 [TBL] [Abstract][Full Text] [Related]
12. [Platelet-function inhibitors in the secondary prevention of ischemic stroke]. Busse O; Diener HC; Grond M Dtsch Med Wochenschr; 2006 Nov; 131 Suppl 5():S132-4. PubMed ID: 17089258 [No Abstract] [Full Text] [Related]
13. Aspirin therapy should be first-line treatment in secondary prevention of stroke--against. Diener HC Stroke; 2002 Aug; 33(8):2138-9. PubMed ID: 12154277 [No Abstract] [Full Text] [Related]
14. [General antithrombotic therapy practice facing fundamental change]. Einecke D MMW Fortschr Med; 2012 Sep; 154(15):24. PubMed ID: 22997933 [No Abstract] [Full Text] [Related]
15. Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke. Redman AR; Ryan GJ Expert Opin Pharmacother; 2004 Jan; 5(1):117-23. PubMed ID: 14680441 [TBL] [Abstract][Full Text] [Related]
16. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Lenz TL; Hilleman DE Ann Pharmacother; 2000 Nov; 34(11):1283-90. PubMed ID: 11098344 [TBL] [Abstract][Full Text] [Related]
18. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. Serebruany VL; Malinin AI; Pokov AN; Hanley DF Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263 [TBL] [Abstract][Full Text] [Related]
19. [Antithrombotic treatment as primary and secondary prevention of stroke]. Chukanova EI; Chukanova AS; Nadareyshvili GG; Gulieva MS Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10):85-88. PubMed ID: 28635860 [TBL] [Abstract][Full Text] [Related]